Maegim한국어

엔젠바이오

354200KOSDAQSector: Others
₩1,825▲ 29.99%Market cap ₩16.3BAs of Jul 21, 2026 close · updated once daily
D
Grade D33.7 ptsTop 81% of 2,523 stocks
Financial strength
9.1
Growth momentum
78.8
Price attractiveness
29.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

9.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
220.2%
✗ Below median · Top 87% in sector
Sector median 80.3%
Can it cover what's due within a year?
Current ratio
50.8%
✗ Below median · Top 91.5% in sector
Sector median 144.8%
How much of revenue becomes profit?
Operating margin
-39.0%
✗ Below median · Top 94.4% in sector
Sector median 4.8%
How much did it earn on its own capital?
ROE (return on equity)
-24.1%
✗ Below median · Top 90.7% in sector
Sector median 5.2%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

78.8
How much did revenue grow in a year?
Revenue growth (YoY)
273.2%
✓ Above median · Top 1.2% in sector
Sector median 3.2%
Has it grown steadily over three years?
Revenue 3-year CAGR
24.5%
✓ Above median · Top 8% in sector
Sector median 0.9%
Did core profits grow in a year?
Operating income change (YoY)
48.5%
✓ Above median · Top 27.7% in sector
Sector median 12.1%
Are core profits higher than three years ago?
Operating income change (3Y)
3.8%
✓ Above median · Top 48.1% in sector
Sector median -0.4%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

29.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
✗ Below median · Top 92.2% in sector
Sector median P/E of profitable peers 10.2x · 26% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.71x
✓ Above median · Top 48.5% in sector
Sector median 0.72x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 136 stocks in Others

S1A20B53C27D28F6